In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reed Miller

Manager, US Commercial and R&D

Washington, DC
Reed, Manager, US Commercial and R&D, got his first real job in journalism in 2000 with The Gray Sheet, then part of FDC Reports, based outside of Washington, DC, and has been covering medical technology ever since. His primary focus has been clinical trials and new product development, so he has covered innumerable FDA advisory panel meetings and Medicare coverage decisions. Mixed in to his many years with The Gray Sheet, Reed spent a year in Massachusetts with HCPro in that company’s pharma compliance editorial group, and three years as a reporter for theheart.org, when it was the best news source for cardiologists. In 2015, he’s became deputy editor of Clinica, continuing to track the bewildering and rapidly evolving universe of new medical technology, from IVDs to artificial hearts, from pre-clinical trials to commercialization. Reed has a BA in religion from the College of William & Mary and an MA in Philosophy of Religion from Boston University. He lives and works in his hometown of State College, Pennsylvania.

Latest From Reed Miller

BD Expects Alaris Infusion Pump To Return To US Market Next Year

The company stopped shipping Alaris in early 2020 after the FDA requested a new 510(k) for modifications and the device has been the subject of several recalls since then.

Recalls Launches

NeoGenomics Bolsters Liquid Diagnostics Portfolio By Acquiring Inivata

Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.

M & A In Vitro Diagnostics

Labcorp Buys Myriad Genetics’ Vectra Autoimmune Test Business

Labcorp has agreed to pay $150m in cash for Myriad Genetics’ autoimmune business, one of three major units Myriad is unloading as it tries to narrow its focus to oncology, women's health and mental health diagnostics.

M & A In Vitro Diagnostics

Boston Scientific Beats Expectations In Q1

Among the company's many milestones in the first quarter, the FDA approved its Therasphere radiation seed device, a major building block of the company's interventional oncology business.

Sales & Earnings Cardiovascular

Device Week, 28 April 2021 – Innovative Technologies In Diabetes; Future Of Surgery

In this week’s podcast, Medtech Insight's Barnaby Pickering features Finnish start-up GlucoModicum, which created a way to measure blood glucose levels without using needles. Managing editor Marion Webb discusses her latest Market Intel, which highlights three companies that developed technologies to help surgeons collaborate with remote surgical experts, including medical device specialists.

Device Week Digital Health

CHF Solutions Renamed Nuwellis As It Expands Beyond Heart Failure Therapy

The company is expanding beyond its traditional focus on heart failure to bring its Aquadex fluid-management technology to more critical care and pediatric patients. Nuwellis’ new ticker symbol on NASDAQ is NUWE.

Business Strategies Cardiovascular
See All
UsernamePublicRestriction

Register